Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hikaru Tanimizu

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
CEN Case Reports|March 17, 2025
Human immunodeficiency virus-associated nephropathy mainly due to cellular variant of focal segmental glomerulosclerosisHikaru Tanimizu, Naoki Sawa, Akinari Sekine, et al.
Internal Medicine (Tokyo, Japan)|August 2, 2023
Apolipoprotein E-associated Lipoprotein Glomerulo-tubulopathyHikaru Tanimizu, Risa Hara, Akinari Sekine, et al.
Clinical Kidney Journal|July 10, 2024
Long-term clinicopathological characteristics of TAFRO syndrome and its relapse: a case series studyYusuke Yoshimura, Hiroki Mizuno, Daisuke Ikuma, et al.
Rheumatology (Oxford, England)|January 25, 2025
Efficacy and safety of first-line targeted synthetic DMARDs in rheumatoid arthritis patients with chronic kidney diseaseYusuke Yoshimura, Masayuki Yamanouchi, Ryo Koizumi, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
CEN Case Reports|March 17, 2025
Human immunodeficiency virus-associated nephropathy mainly due to cellular variant of focal segmental glomerulosclerosisHikaru Tanimizu, Naoki Sawa, Akinari Sekine, et al.
Internal Medicine (Tokyo, Japan)|August 2, 2023
Apolipoprotein E-associated Lipoprotein Glomerulo-tubulopathyHikaru Tanimizu, Risa Hara, Akinari Sekine, et al.
Clinical Kidney Journal|July 10, 2024
Long-term clinicopathological characteristics of TAFRO syndrome and its relapse: a case series studyYusuke Yoshimura, Hiroki Mizuno, Daisuke Ikuma, et al.
Rheumatology (Oxford, England)|January 25, 2025
Efficacy and safety of first-line targeted synthetic DMARDs in rheumatoid arthritis patients with chronic kidney diseaseYusuke Yoshimura, Masayuki Yamanouchi, Ryo Koizumi, et al.
Pageof 1